DOP2021000124A - Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas - Google Patents

Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Info

Publication number
DOP2021000124A
DOP2021000124A DO2021000124A DO2021000124A DOP2021000124A DO P2021000124 A DOP2021000124 A DO P2021000124A DO 2021000124 A DO2021000124 A DO 2021000124A DO 2021000124 A DO2021000124 A DO 2021000124A DO P2021000124 A DOP2021000124 A DO P2021000124A
Authority
DO
Dominican Republic
Prior art keywords
mitochondrial
cscs
modalities
therapeutic agent
stem cells
Prior art date
Application number
DO2021000124A
Other languages
English (en)
Inventor
P Lisanti Michael
Sotgia Federica
Fiorillo Marco
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of DOP2021000124A publication Critical patent/DOP2021000124A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las células madre cancerosas (CSCs) pueden ser erradicadas a través de una estrategia terapéutica novedosa que implica, en algunas modalidades, antibióticos aprobados por la FDA y suplementos dietéticos. El presente planteamiento da por resultado de manera efectiva la erradicación sinérgica de CSCs a través de la inhibición de la biogénesis mitocondrial en CSCs durante el estrés oxidante mitocondrial inducido, sin inhibir las células normales. Las modalidades pueden incluir un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial grande, un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial pequeño y un agente terapéutico que se comporta como un pro-oxidante o induce el estrés oxidante mitocondrial. Las composiciones de acuerdo con el presente planteamiento inhibieron la propagación de CSC por ¿90% en líneas de células MCF7 ER(+) durante estudios preliminares, con una reducción confirmada en el consumo de oxígeno mitocondrial y la producción de ATP. Algunas modalidades incluyen concentraciones sub-antimicrobianas de antibiótico, lo que minimiza en consecuencia los problemas de resistencia a antibióticos. En algunas modalidades, uno o más agentes terapéuticos se conjugan con una señal de fijación de objetivos.
DO2021000124A 2018-12-17 2021-06-17 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas DOP2021000124A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780488P 2018-12-17 2018-12-17
US201962804411P 2019-02-12 2019-02-12
PCT/US2019/066541 WO2020131696A1 (en) 2018-12-17 2019-12-16 Triple combination therapies for targeting mitochondria and killing cancer stem cells

Publications (1)

Publication Number Publication Date
DOP2021000124A true DOP2021000124A (es) 2021-08-15

Family

ID=71102312

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000124A DOP2021000124A (es) 2018-12-17 2021-06-17 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Country Status (20)

Country Link
US (1) US20220040316A1 (es)
EP (1) EP3897658A4 (es)
JP (1) JP7487205B2 (es)
KR (1) KR20210104829A (es)
CN (1) CN113573715A (es)
AU (1) AU2019403048A1 (es)
BR (1) BR112021011963A2 (es)
CA (1) CA3123838A1 (es)
CL (1) CL2021001614A1 (es)
CO (1) CO2021008999A2 (es)
CR (1) CR20210350A (es)
DO (1) DOP2021000124A (es)
EC (1) ECSP21052747A (es)
IL (1) IL284056A (es)
MX (1) MX2021007345A (es)
PE (1) PE20211551A1 (es)
PH (1) PH12021551434A1 (es)
SG (1) SG11202106516VA (es)
WO (1) WO2020131696A1 (es)
ZA (1) ZA202104255B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174464A1 (en) * 2020-05-13 2023-06-08 Lunella Biotech, Inc. Myristoyl derivatives of 9-amino-doxycycline for targeting cancer stem cells and preventing metastasis
WO2023200824A1 (en) * 2022-04-13 2023-10-19 The Wistar Institute Of Anatomy And Biology Delivery system to target gram-negative bacteria

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
CN1837229A (zh) * 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
US20100173024A1 (en) * 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
WO2013024467A2 (en) * 2011-08-18 2013-02-21 Ecole Polytechnique Federale De Lausanne (Epfl) Mitochondrial ribosomal proteins as aging regulators
GB201217310D0 (en) * 2012-09-27 2012-11-14 C10 Pharma As Compounds
CN103536530A (zh) * 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
JP7104134B2 (ja) * 2017-03-15 2022-07-20 ルネラ・バイオテック・インコーポレーテッド ミトリボシン：癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
BR112019024264A2 (pt) 2017-05-19 2020-06-02 Lunella Biotech, Inc. Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer

Also Published As

Publication number Publication date
IL284056A (en) 2021-08-31
PE20211551A1 (es) 2021-08-16
US20220040316A1 (en) 2022-02-10
SG11202106516VA (en) 2021-07-29
ECSP21052747A (es) 2021-08-31
CL2021001614A1 (es) 2022-01-14
KR20210104829A (ko) 2021-08-25
CO2021008999A2 (es) 2021-07-30
AU2019403048A1 (en) 2021-07-08
MX2021007345A (es) 2021-07-15
BR112021011963A2 (pt) 2021-09-08
EP3897658A4 (en) 2022-10-19
WO2020131696A1 (en) 2020-06-25
EP3897658A1 (en) 2021-10-27
PH12021551434A1 (en) 2021-12-06
ZA202104255B (en) 2023-01-25
CR20210350A (es) 2021-09-27
CA3123838A1 (en) 2020-06-25
CN113573715A (zh) 2021-10-29
JP2022516414A (ja) 2022-02-28
JP7487205B2 (ja) 2024-05-20

Similar Documents

Publication Publication Date Title
DOP2021000124A (es) Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas
ECSP19082194A (es) Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
CO2020006472A2 (es) Compuestos de derivados de trifenilfosfonio para erradicar células madre cancerosas
PE20211212A1 (es) AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO
UY39417A (es) Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso
BR112016018085A8 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CO2021002766A2 (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CO2021009008A2 (es) Terapias de combinación triple para anti-envejecimiento
BR112015020178A2 (pt) composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico
UY38965A (es) Composiciones que comprenden canabidiol y flavanonas
CL2020001402A1 (es) Derivados de imidazopiridina y su uso como medicamento.
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
BR112022014650A2 (pt) Derivado de adamantila dissubstituído ou sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para suprimir o crescimento de câncer compreendendo o mesmo como ingrediente ativo
BR112017002911A2 (pt) composição para prevenção ou tratamento de obesidade contendo ácido alfa-lipóico e n-acetilcisteína como ingredientes ativos
Cihan Curcumins antineoplastic, radiosensitizing and radioprotective properties
Shim Synthesis and NRF2 activating ability of thiourea and vinyl sulfoxide derivatives
Magalhães et al. Melissa Officinalis L. ethanolic extract interferes with cell cycle and induces apoptosis of non-small cell lung cancer cells
BRPI0515465A (pt) métodos de inibição do crescimento de célula de tumor e de tratamento de cáncer, incluindo cáncer dependente de hormÈnio e cáncer de próstata e usos de selenato ou sal farmaceuticamente aceitável do mesmo
UY37099A (es) Tratamiento de ulceras gastricas en animales no humanos utilizando formulaciones no recubiertas ni protegidas entéricamente que comprenden polímeros de proantocianidina o extractos botanicos derivados de croton o calophyllum
최승환 et al. Carbon monoxide prevents TNF-α-induced eNOS downregulation by inhibiting NF-κB-responsive miR-155-5p biogenesis
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
PL426617A1 (pl) Suplement diety